Works by Zong, Xiangping

Results: 8

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.

Published in:

Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1219167

By:

Hongzhi Geng;
Sixun Jia;
Ying Zhang;
Jiaqi Li;
Qin Yang;
Liangyu Zeng;
Xiangping Zong;
Yutong Lu;
Shuangzhu Lu;
Jin Zhou;
Caixia Li;
Depei Wu

Publication type:

Article

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.664421

By:

Zhang, Ying;
Li, Jiaqi;
Lou, Xiaoyan;
Chen, Xiaochen;
Yu, Zhou;
Kang, Liqing;
Chen, Jia;
Zhou, Jin;
Zong, Xiangping;
Yang, Zhen;
Li, Minghao;
Xu, Nan;
Jia, Sixun;
Geng, Hongzhi;
Chen, Guanghua;
Dai, Haiping;
Tang, Xiaowen;
Yu, Lei;
Wu, Depei;
Li, Caixia

Publication type:

Article

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R‐CHOP OR R‐CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON‐GERMINAL CENTER B‐CELL SUBTYPE DIFFUSE LARGE B‐CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.

Published in:

HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000971640.48516.5b

By:

Caixia, LI;
Geng, Hongzhi;
Zong, Xiangping;
Zhang, Ying;
Jia, Sixun;
Jiaqi, LI;
Zhou, Jin;
Wu, Depei

Publication type:

Article

PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.

Published in:

2023

By:

Zhang, Ying;
Zong, Xiangping;
LI, Jiaqi;
Jia, Sixun;
Geng, Hongzhi;
Zeng, Liangyu;
Yang, Qin;
Cai, Wenzhi;
Liu, Shuangzhu;
Lu, Yutong;
Yu, Lei;
LI, Caixia;
Wu, Depei

Publication type:

Abstract

ASXL1 mutations are frequent in de novo AML with trisomy 8 and confer an unfavorable prognosis.

Published in:

Leukemia & Lymphoma, 2017, v. 58, n. 1, p. 204, doi. 10.1080/10428194.2016.1179296

By:

Zong, Xiangping;
Yao, Hong;
Wen, Lijun;
Ma, Liang;
Wang, Qinrong;
Yang, Zhiluo;
Zhang, Tongtong;
Chen, Suning;
Depei, Wu

Publication type:

Article

Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma.

Published in:

Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3227

By:

Zhang, Ying;
Geng, Hongzhi;
Zeng, Liangyu;
Li, Jiaqi;
Yang, Qin;
Jia, Sixun;
Zong, Xiangping;
Cai, Wenzhi;
Liu, Shuangzhu;
Lu, Yutong;
Yu, Lei;
Li, Caixia;
Wu, Depei

Publication type:

Article

Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma.

Published in:

Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1430648

By:

Xiangping Zong;
Zhen Yang;
Jin Zhou;
Zhengming Jin;
Depei Wu

Publication type:

Article

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.

Published in:

Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.997589

By:

Jin Zhou;
Ying Zhang;
Meng Shan;
Xiangping Zong;
Hongzhi Geng;
Jiaqi Li;
Guanghua Chen;
Lei Yu;
Yang Xu;
Caixia Li;
Depei Wu

Publication type:

Article